Evidence map›Paper›PMID 38044421›Full record

ArticleMolecular cancer2023

hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma.

Lei Xu, Xiao Ma, Xiuzhong Zhang, Chong Zhang, Yi Zhang, Shuai Gong, Nai Wu, Peng Zhang, Xinyu Feng, Jiaxuan Guo and 3 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Lei Xu *Department of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Xiao Ma *Department of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Xiuzhong Zhang *Department of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Chong ZhangDepartment of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yi ZhangDepartment of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Shuai GongDepartment of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Nai WuDepartment of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Peng ZhangDepartment of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Xinyu FengDepartment of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Jiaxuan GuoDepartment of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Mengmeng ZhaoDepartment of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Zeqiang RenDepartment of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. rzq0805@163.com.
Pengbo ZhangDepartment of General Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. zpb_ok@126.com.
Xuzhou Medical College · CNAffiliated Hospital of Xuzhou Medical College · CNXuzhou No.1 People's Hospital · CN

Funding

Science and Technology Project of Xuzhou Municipal Health Commission XWKYHT20220152Xuzhou Medical University Affiliated Hospital Development Fund XYFY2021017
6 · The paper itself

Abstract

backgroundCircular RNAs (circRNAs) play important roles in the occurrence and development of cancer and chemoresistance. DNA damage repair contributes to the proliferation of cancer cells and resistance to chemotherapy-induced apoptosis. However, the role of circRNAs in the regulation of DNA damage repair needs clarification.

methodsRNA sequencing analysis was applied to identify the differentially expressed circRNAs. qRT-PCR was conducted to confirm the expression of hsa_circ_0007919, and CCK-8, FCM, single-cell gel electrophoresis and IF assays were used to analyze the proliferation, apoptosis and gemcitabine (GEM) resistance of pancreatic ductal adenocarcinoma (PDAC) cells. Xenograft model and IHC experiments were conducted to confirm the effects of hsa_circ_0007919 on tumor growth and DNA damage in vivo. RNA sequencing and GSEA were applied to confirm the downstream genes and pathways of hsa_circ_0007919. FISH and nuclear-cytoplasmic RNA fractionation experiments were conducted to identify the cellular localization of hsa_circ_0007919. ChIRP, RIP, Co-IP, ChIP, MS-PCR and luciferase reporter assays were conducted to confirm the interaction among hsa_circ_0007919, FOXA1, TET1 and the LIG1 promoter.

resultsWe identified a highly expressed circRNA, hsa_circ_0007919, in GEM-resistant PDAC tissues and cells. High expression of hsa_circ_0007919 correlates with poor overall survival (OS) and disease-free survival (DFS) of PDAC patients. Hsa_circ_0007919 inhibits the DNA damage, accumulation of DNA breaks and apoptosis induced by GEM in a LIG1-dependent manner to maintain cell survival. Mechanistically, hsa_circ_0007919 recruits FOXA1 and TET1 to decrease the methylation of the LIG1 promoter and increase its transcription, further promoting base excision repair, mismatch repair and nucleotide excision repair. At last, we found that GEM enhanced the binding of QKI to the introns of hsa_circ_0007919 pre-mRNA and the splicing and circularization of this pre-mRNA to generate hsa_circ_0007919.

conclusionsHsa_circ_0007919 promotes GEM resistance by enhancing DNA damage repair in a LIG1-dependent manner to maintain cell survival. Targeting hsa_circ_0007919 and DNA damage repair pathways could be a therapeutic strategy for PDAC.

Indexed as

Carcinoma, Pancreatic DuctalMicroRNAsPancreatic NeoplasmsCell Line, TumorCell ProliferationDNA DamageDNA Ligase ATPGemcitabineHepatocyte Nuclear Factor 3-alphaHumansMixed Function OxygenasesProto-Oncogene ProteinsRNA, CircularRNA PrecursorsDNA Ligase ATPFOXA1 protein, humanGemcitabineHepatocyte Nuclear Factor 3-alphaLIG1 protein, humanMicroRNAsMixed Function OxygenasesProto-Oncogene ProteinsRNA, CircularRNA PrecursorsTET1 protein, humanDNA damage repairhsa_circ_0007919LIG1Pancreatic ductal adenocarcinomaQKI

Identifiers

PMID38044421
PMCPMC10694898
OpenAlexW4389289208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.